Kiora Pharmaceuticals and Spero Therapeutics Listed on Nasdaq
What happened
Kiora Pharmaceuticals and Spero Therapeutics are listed on Nasdaq. A report comparing the two small-cap healthcare companies contrasts their financial characteristics, including risk, profitability, and valuation. The report notes that Spero Therapeutics has higher revenue and earnings than Kiora Pharmaceuticals, while Kiora Pharmaceuticals trades at a lower price-to-earnings ratio.
From tickerreport.com
Why it matters
The comparison provides insight into the relative financial health and risk profiles of the two companies. Kiora Pharmaceuticals has a beta of -0.22, indicating lower volatility compared to Spero Therapeutics, which has a beta of 1.5. Furthermore, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors, compared to 25.6% of Spero Therapeutics shares.
From tickerreport.com
Who's involved
- NasdaqThe stock exchange where Kiora Pharmaceuticals and Spero Therapeutics are listed
- CellectisA biopharmaceutical company whose stock listing is dependent on Nasdaq infrastructure
- Cronos Group IncA company listed and trading on the Nasdaq exchange
Keep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
Related events
- MarketBeat provided an average rating for AleAnna Inc., which is listed on Nasdaq and focuses on assets in Italy, after Royal Bank of Canada purchased its shares.
- Global Mofy AI Limited was listed on the stock exchange and received a consensus rating from MarketBeat.
- Sensei Biotherapeutics, Inc. trades on Nasdaq, receives consensus rating data from MarketBeat, and William Blair begins coverage.
- Argo Blockchain is listed on Nasdaq, and MarketBeat is reporting on the company's status.
- Praxis Precision Medicines listed its shares on the Nasdaq stock exchange on July 17, 2026.